NL-OMON32559尚未招募不适用
Routine manual hyperinflation versus on demand manual hyperinflation in intubated and mechanically ventilated post*cardiothoracic surgery patients * A randomized controlled trial * - Routine Manual Hyperinflation vs On Demand Manual Hyperinflation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients planned for coronary artery bypass grafting and/or valve surgery are recruited
- •> 18 years of age
- •written informed consent
排除标准
- •(Previous) pulmonary surgery
- •Pulmonary infection
研究者
相似试验
进行中（未招募）
不适用
A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisMedDRA version: 9.1Level: LLTClassification code 10002026Term: Amyotrophic lateral sclerosisEUCTR2004-002855-15-ITOVARTIS FARMA476
已完成
4 期
To evaluate the performance of Portico & Navitor heart Valve in Indian patientsCTRI/2022/04/041689Abbott India Pvt Ltd30
进行中（未招募）
不适用
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral SclerosisEUCTR2004-002855-15-DEovartis Pharma Services AG480
进行中（未招募）
不适用
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral SclerosisEUCTR2004-002855-15-GBovartis Pharma Services AG480
进行中（未招募）
不适用
A randomised study comparing placebo and a not yet approved drug CS1008, in combination with drugs Carboplatin and Paclitaxel in patients with non small cell lung cancer which has spread or can not be removed by surgery, who have not had chemotherapy treatment before. The study is double-blind (that is when neither the patient nor the investigator know which treatment the patient is receiving).Treatment of metastatic or unresectable non small cell lung cancer (NSCLC) with CS 1008 or placebo first in combination with carboplatin/paclitaxel then as monotherapy in the first line settingMedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004574-11-DEDaiichi Sankyo Development Limited120